NY-REPLICOR
7.6.2016 14:01:56 CEST | Business Wire | Press release
Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces the publication of clinical data from its REP 101 and REP 102 studies demonstrating the therapeutic effect of nucleic acid polymers (NAPs) in patients with HBeAg positive chronic HBV infection in the journal PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0156667 ).
The REP 101 study (NCT02646163) assessed the safety and efficacy of Replicor’s first clinical NAP candidate, REP 2055, as a weekly monotherapy in patients with HBeAg positive chronic HBV infection. The follow-on REP 102 study (NCT02646189), conducted in similar patients, used an improved NAP candidate (REP 2139) in an improved formulation with better administration tolerability (REP 2139-Ca) and included transition from monotherapy to brief (13-26 weeks) combination therapy with thymosin alpha 1 or pegylated interferon alpha 2a.
In both studies, NAP monotherapy was accompanied by 2 – 7 log reductions of serum HBsAg, 3 – 9 log reductions in serum HBV DNA, seroconversion of HBeAg and the appearance of serum anti-HBsAg antibodies. Self-resolving flares in liver transaminases in many patients (considered indirect evidence of antiviral immune activity in the liver) which peaked during the clearance of serum viremia were also observed. In the REP 102 study, 9 patients transitioned to combined treatment with immunotherapy during which 8 experienced HBsAg loss and all 9 experienced rapid and dramatic increases in serum anti-HBsAg antibody titers before withdrawal of therapy.
After REP 2055 treatment, 3 / 8 patients maintained control of infection for 1 year and two of these patients have still maintained control 5 years off-treatment. After combination therapy in the REP 102 study, 8 of 9 patients maintained control of infection after treatment which has persisted for more than 2 years in four of these patients.
Based on these initial studies, an optimized NAP-based combination therapy is currently being evaluated in HBeAg negative chronic HBV infection in the REP 401 protocol (NCT02565719), which has the potential to more easily achieve the functional control of chronic HBV infection with a finite course of treatment.
About Replicor
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160607005253/en/
Contact:
Media:
For Replicor Inc.
Alexandra Peterson,
212-508-9709
apeterson@makovsky.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy EI Residential Solar-plus-Storage Solution Certified with Romanian Grid Operators9.2.2026 06:00:00 CET | Press release
With approval from Distribuție Energie Electrică România (DEER), Distribuție Oltenia, and Rețele Electrice, Tigo expands offering in one of Europe’s fastest-growing residential solar markets. Tigo Energy, Inc. (NASDAQ: “TYGO”) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced the successful certification of the Tigo EI Residential solar-plus-storage solution with Romanian distribution system operators, further expanding market reach of Tigo products across Europe. Following the successful completion of their respective grid-compliance and certification procedures with Distribuție Energie Electrică Romania (DEER), Distribuție Oltenia, and Rețele Electrice, single-phase and three-phase configurations of the EI Residential solution are now fully listed and approved for use in the Romanian market. With 2026 expected to be another strong year for solar growth nationally, the Tigo EI Residential system becomes an important addition
Levi’s® Brand Debuts “Behind Every Original” Campaign With Super Bowl Film Highlighting Backstories and Backsides9.2.2026 01:38:00 CET | Press release
The Levi’s® brand today launched “Behind Every Original,” a bold new global campaign that celebrates the people who push culture forward — with one cheeky twist. Debuting during the Super Bowl with the anthem film “Backstory,” directed by Kim Gehrig, the Levi’s® brand flips expectations by showcasing both celebrity icons and everyday Originals exclusively from the backside, letting them share their game-changing Levi’s® backstory. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260208761156/en/ Doechii Why the backside? Because it's the most iconic point of view of Levi’s® jeans. The arcuate stitching, silhouette and the Red Tab™ instantly signal originality. For over 150 years, Levi’s® jeans have been the uniform of cultural catalysts who step off the beaten path and shape what comes next in music, sport, fashion and art. They have been the uniform of the movements and moments that have changed the world and shaped culture —
DCO Concludes 5th General Assembly with Adoption of the Kuwait Declaration on Responsible AI for Global Digital Prosperity7.2.2026 16:41:00 CET | Press release
The Digital Cooperation Organization (DCO) has concluded its fifth General Assembly, with Member States adopting the Kuwait Declaration on Responsible AI for Global Digital Prosperity and agreeing on actions to advance inclusive, trusted, and scalable digital transformation in the AI age. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207972901/en/ DCO concludes 5th General Assembly with adoption of the Kuwait Declaration on Responsible AI for Global Digital Prosperity (Photo: AETOSWire) Convened on 4–5 February 2026 under the Presidency of the State of Kuwait, the General Assembly brought together Ministers and Representatives of Member States, alongside Observers, partners, and guest countries, to review progress against the DCO 4-Year Agenda (2025–2028), take joint decisions on multilateral initiatives, and translate shared ambition on AI into delivery. Ministers and representatives reaffirmed their commitment to inclu
Rapid Medical™’s DISTALS Trial Overwhelmingly Positive, Demonstrating Superior Reperfusion with TIGERTRIEVER™ 13 in Medium Vessel Stroke6.2.2026 20:30:00 CET | Press release
TIGERTRIEVER™ 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in smaller but critical areas of the brain, accounting for almost 50% of all ischemic strokes Rapid Medical™, a leading developer of active endovascular devices, today announced late-breaking results from the DISTALS multicenter, randomized controlled trial showing that TIGERTRIEVER™ 13 achieved superior brain tissue reperfusion with an excellent safety profile when compared with medical management in medium vessel occlusion (MVO) stroke. The findings were presented in the main closing session at the 2026 International Stroke Conference (ISC). Top-line results showed that the TIGERTRIEVER™ 13 arm demonstrated 3x more successful reperfusion without symptomatic intracranial hemorrhage (sICH) compared to medical management–86.3% vs 27.7% (p < 0.001). Notably, zero sICH events were reported in the randomized treatment arm treated with TIGERTRIEVER 13. By comparison, sICH rates rep
Al Barari Breaks Ground on The Cape, The Final Chapter of a Legacy6.2.2026 15:46:00 CET | Press release
Al Barari, Dubai’s pioneering nature-led community, has officially marked the groundbreaking of The Cape, its final signature residential development, celebrating two decades of visionary craftsmanship and a continued commitment to creating harmonious living environments rooted in nature. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206475199/en/ Hazza Zaal, CEO of Al Barari Real Estate Group, alongside the Sales and Construction teams at The Cape Groundbreaking Ceremony, marking a milestone in Al Barari’s final signature development. (Photo: AETOSWire) The milestone ceremony signals the beginning of a landmark chapter for Al Barari, as The Cape represents the culmination of a 20-year legacy defined by intentional design, wellbeing-focused living, and immersive natural landscapes. Located within Dubai’s green heart, The Cape introduces an enriched lifestyle experience surrounded by lush botanical settings, gentle water
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom